Announced on | Meeting on |
Jul 15, 2024 | Jul 22, 2024 |
Quarterly Results | |
May 21, 2024 | May 29, 2024 |
Audited Results | |
May 07, 2024 | May 09, 2024 |
To consider Fund Raising | |
Feb 05, 2024 | Feb 14, 2024 |
Quarterly Results | |
Nov 08, 2023 | Nov 14, 2023 |
Quarterly Results |
Solara Active Pharma Sciences Share Price
- Open702.00
- High705.00
- Low670.00
- Prev Close694.40
- Volume39,756
- VWAP(₹)695.15
Solara Active Pharma share price insights
Losing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Consolidated Financials)PAT: Troublesome Times
Company has posted a loss of Rs 13.46 cr for the 4th consecutive quarter. (Source: Consolidated Financials)Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -57.41% as compared to Nifty Smallcap 100 which gave a return of 92.43%. (as of last trading session)Employee & Interest Expense
Company has spent 8.15% of its operating revenues towards interest expenses and 18.92% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)Solara Active Pharma Share Price Update
Solara Active Pharma Sciences Ltd. share price moved up by 1.44% from its previous close of Rs 694.40. Solara Active Pharma Sciences Ltd. stock last traded price is 704.35
Share Price Value Today/Current/Last 704.35 Previous Day 694.40
Solara Active Pharma Share Price Returns
1 Day | 1.44% |
1 Month | 16.51% |
3 Months | 64.15% |
1 Year | 91.4% |
3 Years | -56.8% |
5 Years | 59.77% |
Key Metrics
PE Ratio(x) | -6.02 |
EPS - TTM(₹) | -116.93 |
MCap(₹ Cr.) | 3,381.16 |
MCap Rank | 58 |
PB Ratio(x) | 3.56 |
Div Yield(%) | 0.00 |
Face Value(₹) | 10.00 |
52W High(₹) | 757.20 |
52W Low(₹) | 308.25 |
MCap/Sales | 1.04 |
Beta(1 Month) | 1.98 |
BV/Share(₹) | 195.10 |
Solara Active Pharma Share Recommendations
1 Analysts
SellSellHoldBuyStrong
Buy
Ratings | Current | 1W Ago | 1M Ago | 3M Ago |
---|---|---|---|---|
Strong Buy | - | - | - | 1 |
Buy | - | - | - | - |
Hold | - | - | - | - |
Sell | - | - | - | - |
Strong Sell | 1 | 1 | 1 | 1 |
# Analysts | 1 | 1 | 1 | 2 |
Solara Active Pharma News & Analysis
NewsStocks in news: Godrej Properties, Whirlpool, Solara Active Pharma, TCS, Nestle India
NewsStocks in news: Tata Motors, Bank of Baroda, Cipla, BPCL, Manappuram Finance
NewsOnly 39 smallcap stocks rise in double-digits as geopolitical concerns, lofty valuations weigh Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcements
Solara Active Pharma Financials
Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Total Income 364.05 301.13 249.18 426.42 354.35 Total Income Growth (%) 20.89 20.85 -41.56 20.34 -8.03 Total Expenses 346.64 437.10 499.15 419.04 359.10 Total Expenses Growth (%) -20.70 -12.43 19.12 16.69 0.22 EBIT 17.41 -135.97 -249.97 7.38 -4.75 EBIT Growth (%) - - -3,487.13 - -117.59 Profit after Tax (PAT) -13.46 -255.34 -275.34 -17.16 -19.55 PAT Growth (%) - - - - -618.57 EBIT Margin (%) 4.78 -45.15 -100.32 1.73 -1.34 Net Profit Margin (%) -3.70 -84.79 -110.50 -4.02 -5.52 Basic EPS (₹) -3.50 -70.93 -76.49 -4.77 -5.43 All figures in Rs Cr, unless mentioned otherwise
InsightsPAT: Troublesome Times
Company has posted a loss of Rs 13.46 cr for the 4th consecutive quarter. (Source: Consolidated Financials)Employee & Interest Expense
Company has spent 8.15% of its operating revenues towards interest expenses and 18.92% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 2,350.96 2,899.28 2,952.53 2,613.58 2,153.50 Total Assets Growth (%) -18.91 -1.80 12.97 21.36 9.87 Total Liabilities 1,414.38 1,396.83 1,425.35 1,020.82 1,063.27 Total Liabilities Growth (%) 1.26 -2.00 39.63 -3.99 6.35 Total Equity 936.58 1,502.45 1,527.18 1,592.76 1,090.23 Total Equity Growth (%) -37.66 -1.62 -4.12 46.09 13.54 Current Ratio (x) 0.64 1.08 1.16 1.34 0.92 Total Debt to Equity (x) 1.07 0.67 0.67 0.32 0.59 Contingent Liabilities 0.00 38.00 66.88 104.50 73.51 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities 108.87 156.25 -242.03 155.46 244.22 Net Cash used in Investing Activities -3.51 -81.14 -242.85 -106.30 -358.81 Net Cash flow from Financing Activities -105.65 -112.76 333.57 92.49 94.91 Net Cash Flow -0.29 -37.65 -151.31 141.65 -19.68 Closing Cash & Cash Equivalent 8.44 8.73 46.38 197.69 56.04 Closing Cash & Cash Equivalent Growth (%) -3.32 -81.18 -76.54 252.77 -25.99 Total Debt/ CFO (x) 9.18 6.41 -4.23 3.32 2.40 All figures in Rs Cr, unless mentioned otherwise
InsightsDecrease in Cash from Investing
Company has used Rs 3.51 cr for investing activities which is an YoY decrease of 95.67%. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) -60.76 -1.47 -3.81 13.93 11.57 Return on Capital Employed (%) -17.42 2.51 -0.65 16.76 13.54 Return on Assets (%) -24.13 -0.76 -1.96 8.47 5.32 Interest Coverage Ratio (x) -0.85 1.74 1.33 3.62 2.48 Asset Turnover Ratio (x) 0.49 0.49 0.46 61.86 61.37 Price to Earnings (x) -2.36 -53.48 -41.32 22.62 10.38 Price to Book (x) 1.44 0.79 1.57 3.15 1.20 EV/EBITDA (x) -26.00 13.92 33.75 12.85 6.01 EBITDA Margin (%) -6.96 10.83 7.88 25.64 21.71 InsightsLosing Shareholder's Money
Company has reported a negative ROE for 3 consecutive years. (Source: Consolidated Financials)
Peer Comparison
NAME 1D 1W 1M 3M 1Y 3Y 5Y Solara Active Pharma Stock Performance 1.44 1.09 14.17 60.90 91.87 -56.80 62.22 Morepen Labs Stock Performance -3.28 10.61 32.48 62.38 99.05 47.90 385.09 Indoco Remedies Stock Performance -0.13 3.81 13.12 16.01 12.99 -18.83 162.96 Dishman Carbogen Stock Performance -0.94 6.43 18.86 4.15 27.98 9.44 18.09 Suven Life Sci Stock Performance -3.62 -2.81 -3.21 49.54 119.33 70.47 -44.02 All values in %
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of -57.41% as compared to Nifty Smallcap 100 which gave a return of 92.43%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated -57.41% return as compared to Nifty Pharma which gave investors 64.81% return over 3 year time period. (as of last trading session)
Mutual Funds Ownership
No Data Available
Corporate Actions
Board Meeting
Quarterly Results
Jul 15, 2024
Board Meeting
Audited Results
May 21, 2024
Board Meeting
To consider Fund Raising
May 07, 2024
Announced on Ex-Date Dividend% May 06, 2021 Aug 18, 2021 30% Nov 06, 2020 Nov 19, 2020 40% May 07, 2020 Jul 28, 2020 20% May 16, 2019 Aug 06, 2019 50% No Data Available
No Data Available
Announced on Ex-Date Jul 05, 2023 May 15, 2024 Rights ratio: 1 share for every 3 held at a price of Rs 375.0 Announced on Meeting on Mar 11, 2024 Apr 08, 2024 - Dec 20, 2023 Jan 20, 2024 - Aug 21, 2023 Sep 15, 2023 A.G.M. Jan 27, 2023 Feb 28, 2023 - May 02, 2022 Jun 03, 2022 -
About
Solara Active Pharma Sciences Ltd., incorporated in the year 2017, is a Small Cap company (having a market cap of Rs 3,381.16 Crore) operating in Pharmaceuticals sector.
Solara Active Pharma Sciences Ltd. key Products/Revenue Segments include Active Pharma Ingredients, Other Operating Revenue and Sale of services for the year ending 31-Mar-2023.
For the quarter ended 30-06-2024, the company has reported a Consolidated Total Income of Rs 364.05 Crore, up 20.89 % from last quarter Total Income of Rs 301.13 Crore and up 2.74 % from last year same quarter Total Income of Rs 354.35 Crore. Company has reported net profit after tax of Rs -13.46 Crore in latest quarter.
The company’s top management includes Mr.Poorvank Purohit, Mr.Ankur Nand Thadani, Mr.Arun Kumar, Mr.Kartheek Chintalapati Raju, Dr.Kausalya Santhanam, Mr.R Ramakrishnan, Mr.S Hariharan, Mr.M Mohan, Mr.S Murali Krishna. Company has Deloitte Haskins & Sells LLP as its auditors. As on 30-06-2024, the company has a total of 4.80 Crore shares outstanding.
About Solara Active Pharma
Solara Active Pharma Sciences Ltd., incorporated in the year 2017, is a Small Cap company (having a market cap of Rs 3,381.16 Crore) operating in Pharmaceuticals sector. Solara Active Pharma Sciences Ltd. key Products/Revenue Segments include Active Pharma Ingredients, Other Operating Revenue and Sale of services for the year ending 31-Mar-2023.For the quarter ended 30-06-2024, the company has reported a Consolidated Total Income of Rs 364.05 Crore, up 20.89 % from last quarter Total Income of Rs 301.13 Crore and up 2.74 % from last year same quarter Total Income of Rs 354.35 Crore. Company has reported net profit after tax of Rs -13.46 Crore in latest quarter.The company’s top management includes Mr.Poorvank Purohit, Mr.Ankur Nand Thadani, Mr.Arun Kumar, Mr.Kartheek Chintalapati Raju, Dr.Kausalya Santhanam, Mr.R Ramakrishnan, Mr.S Hariharan, Mr.M Mohan, Mr.S Murali Krishna. Company has Deloitte Haskins & Sells LLP as its auditors. As on 30-06-2024, the company has a total of 4.80 Crore shares outstanding.
Industry
Key Indices Listed On
BSE SmallCap, BSE Healthcare, BSE AllCap, Nifty MidSmall Healthcare, BSE MidSmallCap
Address
201, Devavrata,Sector 17, Vashi,New Mumbai, Maharashtra - 400703
Executive Leadership
Poorvank Purohit
Managing Director & CEOAnkur Nand Thadani
Non Executive DirectorArun Kumar
Non Executive DirectorKartheek Chintalapati Raju
Non Executive DirectorAuditors
FAQs about Solara Active Pharma share
- 1. What's the Solara Active Pharma share price today?Solara Active Pharma share price was Rs 704.35 as on 29 Aug, 2024, 03:59 PM IST. Solara Active Pharma share price was up by 1.44% based on previous share price of Rs 698.6. Solara Active Pharma share price trend:
- Last 3 Months: Solara Active Pharma share price moved up by 64.15%
- Last 12 Months: Solara Active Pharma share price moved up 91.40%
- Last 3 Years: Solara Active Pharma Share price moved down by 56.80%
- 2. What is Solara Active Pharma's 52 week high / low?Solara Active Pharma share price saw a 52 week high of Rs 757.20 and 52 week low of Rs 308.25.
- 3. What is the market cap of Solara Active Pharma?Solara Active Pharma share has a market capitalization of Rs 3,381.16 Cr. Within Pharmaceuticals sector, it's market cap rank is 58.
- 4. What is the CAGR of Solara Active Pharma?The CAGR of Solara Active Pharma is -5.51.
- 5. Who is the CEO of Solara Active Pharma?Poorvank Purohit is the Managing Director & CEO of Solara Active Pharma
- 6. What are the returns for Solara Active Pharma share?Return Performance of Solara Active Pharma Shares:
- 1 Week: Solara Active Pharma share price moved down by 2.95%
- 3 Month: Solara Active Pharma share price moved up by 64.15%
- 6 Month: Solara Active Pharma share price moved up by 58.26%
- 7. What dividend is Solara Active Pharma giving?Solara Active Pharma Sciences Ltd. announced an equity dividend of 30% on a face value of 10.0 amounting to Rs 3 per share on 06 May 2021. The ex dividend date was 18 Aug 2021.
- 8. What is the PE & PB ratio of Solara Active Pharma?The PE ratio of Solara Active Pharma stands at -5.94, while the PB ratio is 2.67.
- 9. Which are the key peers to Solara Active Pharma?Top 10 Peers for Solara Active Pharma are SMS Pharmaceuticals Ltd., IOL Chemicals and Pharmaceuticals Ltd., Themis Medicare Ltd., Amrutanjan Health Care Ltd., Dishman Carbogen Amcis Ltd., Suven Life Sciences Ltd., Indoco Remedies Ltd., Zota Healthcare Ltd., Morepen Laboratories Ltd. and Syncom Formulation (India) Ltd.
- 10. Who owns Solara Active Pharma?Following are the key changes to Solara Active Pharma shareholding:
- Promoter holding has gone up from 37.19 (30 Sep 2023) to 37.27 (30 Jun 2024)
- Domestic Institutional Investors holding has gone up from 1.75 (30 Sep 2023) to 2.8 (30 Jun 2024)
- Foreign Institutional Investors holding have gone down from 17.86 (30 Sep 2023) to 14.0 (30 Jun 2024)
- Other investor holding has gone up from 43.2 (30 Sep 2023) to 45.93 (30 Jun 2024)
- 11. Should I buy, sell or hold Solara Active Pharma?As per Refinitiv (erstwhile Thomson Reuters), overall mean recommendation by 1 analyst for Solara Active Pharma stock is to Strong Sell. Recommendation breakup is as follows
- 1 analyst is recommending Strong Sell
- 12. What are the key metrics to analyse Solara Active Pharma Share Price?Key Metrics for Solara Active Pharma are:
- PE Ratio of Solara Active Pharma is -6.02
- Price/Sales ratio of Solara Active Pharma is 1.04
- Price to Book ratio of Solara Active Pharma is 3.56
- 13. What are the Solara Active Pharma quarterly results?Total Revenue and Earning for Solara Active Pharma for the year ending 2024-03-31 was Rs 1294.29 Cr and Rs -567.39 Cr on Consolidated basis. Last Quarter 2024-06-30, Solara Active Pharma reported an income of Rs 364.05 Cr and loss of Rs -13.46 Cr.
Trending in Markets
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.